Found 7 matching trials
Go-CHOP as the Frontline Therapy for PTCL PHASE2 This is a phase 2 Study to investigate the safety, tolerability, and anti-t...
Show More Location
Henan Cancer Hospital
Learn More & Join Trial
Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients PHASE2 The goal of this observational study is to evaluate the safety and efficacy...
Show More Location
Multiple Locations
Learn More & Join Trial
Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) PHASE2 This study will treat patients with newly diagnosed PTCL, who have no prior...
Show More Location
Sun Yat-sen University Cancer Center
Learn More & Join Trial
Golidocitinib Plus CHOP in Newly Diagnosed PTCL PHASE1 This is single-arm phase I/II study designed to evaluate the safety and eff...
Show More Location
Peking Union Medical College Hospital
Learn More & Join Trial
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study PHASE2 To learn if the study drug golidocitinib given alone or in combination with...
Show More Location
MD Anderson Cancer Center
Learn More & Join Trial
New Genotype-guided Treatment in Newly Diagnosed PTCL PHASE1 This is a phase I/II study evaluate the safety and efficacy targeted agents...
Show More Learn More & Join Trial
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) PHASE1 This is a phase 1/2 open-label study to evaluate GW5282 in combination with...
Show More Location
Chongqing Cancer Hospital
Learn More & Join Trial